Gapping up
In reaction to earnings/guidance:
- CGNX +11.9%, SWAV +11.3%, APPN +10.7%, LTHM +9.7%, BLMN +7.6%, ASPN +6.1% (also announces $150 mln investment from Koch Strategic Platforms; also to construct an advanced manufacturing facility), HASI +6.1% (also increases dividend), AMN +6%, QDEL +5.7%, AJRD +4.6%, AL +4.1%, RRD +3.1%, MATX +2.9%, CRON +2.9%, EXEL +2.5%, ATR +2.1%, CWST +2%, TSLX +1.7%, PK +1.4%, DLR +1.2%, GLOB +1.2%, LTC +1.2%, DE +1.2%, .
Other news:
- SAND +8.1% (to sell certain non-royalty and non-stream assets to Royalty North)
- CNA +5.7% (files mixed securities shelf offering)
- DD +4.8% (Celanese acquires majority of DuPont's Mobility & Materials Business for $11 bln)
- RCEL +3.5% (FDA approves PMA supplement for RECELL US product launch planned for Q2)
- EFC +3.5% (reports estimated book value per share)
- FTV +3.2% (approves 20 mln share repurchase program)
- MHO +2.9% (approves $100 mln increase to existing share repurchase authorization)
- XOS +2.6% (enters into dealership agreements with MHC Xos) CE +2.5% (Celanese acquires majority of DuPont's Mobility & Materials Business for $11 bln)
- OBSV +2.2% (stock offering)
- BLDR +2.2% (to repurchase $1 bln of its common shares)
- HLTH +1.5% (HLTH partners with CAH expand distribution of HLTH's COVID-19 tests)
- ONB +1% (announces $200 mln stock repurchase authorization)
- NVS +1% (Sandoz unit launches generic lenalidomide in 19 countries across Europe)
- CLNN +1% (to Present Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2022)
Analyst comments:
- FSLY +3% (upgraded to Strong Buy from Outperform at Raymond James)
- IRDM +2% (upgraded to Strong Buy from Outperform at Raymond James)
- BEKE +1.7% (upgraded to Buy from Neutral at Goldman)